Lilley & Co’s Pfizer PFE Stock Holding History

Lilley & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$707K	Sell	25,104 -4,522	-15%	-$129K	0.32%	61
2014 Q1	$903K	Buy	29,626 +313	+1%	+$9.33K	0.41%	57
2013 Q4	$852K	Buy	29,313 +6,102	+26%	+$178K	0.4%	58
2013 Q3	$633K	Buy	23,211 +2,256	+11%	+$61.4K	0.33%	63
2013 Q2	$557K	Buy	+20,955	New	+$579K	0.3%	64

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Lilley & Co's PFE Position: Q2 2014 in Review

Lilley & Co reduced its Pfizer (PFE) stake by 15% in Q2 2014, selling an estimated $129K and leaving 25,104 shares worth $707K. The position accounts for 0.32% of the portfolio, ranked #61.

Lilley & Co first reported a position in PFE in Q2 2013 and has held it in 5 quarters since. The position peaked at $903K in Q1 2014. 1,745 funds tracked by Wall St. Rank hold PFE as of Q2 2014.

Lilley & Co held 25,104 shares of Pfizer worth $707K as of Q2 2014.
Lilley & Co sold 4,522 Pfizer shares in Q2 2014, an estimated $129K.
Pfizer made up 0.32% of Lilley & Co's portfolio in Q2 2014, its #61 holding.
Lilley & Co first reported a position in Pfizer in Q2 2013 and has held it in 5 quarters since.
Lilley & Co's Pfizer position peaked at $903K in Q1 2014.
1,745 funds tracked by Wall St. Rank held Pfizer as of Q2 2014.

Based on Lilley & Co's 13F filing for Q2 2014, filed 14 Jul 2014.